kalvista - Search News

News

KalVista, Hereditary Angioedema and FDA

US FDA approves KalVista's oral swelling disorder drug, shares rise

KalVista Pharmaceuticals said on Monday the U.S. Food and Drug Administration has approved its drug, the first on-demand oral treatment for a type of hereditary swelling disorder, sending its shares up more than 18%.

Business Wire · 2d

KalVista Pharmaceuticals Announces FDA Approval of EKTERLY® (sebetralstat), First and Only Oral On-demand Treatment for Hereditary Angioedema

KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that the U.S. Food and Drug Administration (FDA) has approved EKTERLY® (sebetralstat), a novel

PharmExec · 22h

FDA Approves KalVista Pharmaceuticals’ Ekterly for Hereditary Angioedema

Ekterly becomes the first FDA-approved oral on-demand treatment for hereditary angioedema in patients aged 12 years and older.

BioSpace1h

Second Half Milestones, KalVista’s Surprise Approval, Another RFK Jr. Lawsuit, More

H2 2025 catalysts to watch, biopharma implications of President Trump’s tax law, KalVista’s new hereditary angioedema drug that Marty Makary reportedly tried to reject, another lawsuit aimed at Health ...

Orsini Selected as Specialty Pharmacy Partner for KalVista's EKTERLY® (sebetralstat)

Orsini, a leader in rare disease pharmacy solutions, has been chosen by KalVista Pharmaceuticals as a specialty pharmacy ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results

News

KalVista, Hereditary Angioedema and FDA

Trending now